Niagen Bioscience (NAGE) Shares Outstanding (Weighted Average) (2011 - 2026)

Niagen Bioscience (NAGE) has 16 years of Shares Outstanding (Weighted Average) data on file, last reported at $79.9 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $79.9 million, up 2.71% year-over-year; the trailing twelve-month figure through Mar 2026 was $79.9 million (up 2.71% YoY), and the FY2025 annual result was $79.2 million, up 4.28% from the prior year.
• Shares Outstanding (Weighted Average) grew to $79.9 million in Q1 2026 per NAGE's latest filing, from $79.2 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $79.9 million in Q1 2026 and troughed at $68.3 million in Q1 2022.
• A 5-year average of $74.8 million and a median of $75.2 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2023 and 2024: Shares Outstanding (Weighted Average) advanced 9.65% in 2023, then grew 0.58% in 2024.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $69.7 million in 2022, then advanced by 7.54% to $75.0 million in 2023, then advanced by 1.26% to $75.9 million in 2024, then rose by 4.28% to $79.2 million in 2025, then advanced by 0.93% to $79.9 million in 2026.
• Business Quant data shows NAGE's Shares Outstanding (Weighted Average) at $79.9 million in Q1 2026, $79.2 million in Q4 2025, and $79.0 million in Q3 2025.